Literature DB >> 15640629

De-escalation therapy in ventilator-associated pneumonia.

Jordi Rello1, Loreto Vidaur, Alberto Sandiumenge, Alejandro Rodríguez, Belen Gualis, Carmen Boque, Emili Diaz.   

Abstract

OBJECTIVE: To evaluate de-escalation of antibiotic therapy in patients with ventilator-associated pneumonia.
DESIGN: Prospective observational study during a 43-month period.
SETTING: Medical-surgical intensive care unit. PATIENTS: One hundred and fifteen patients admitted to the intensive care unit with clinical diagnosis of ventilator-associated pneumonia. All the episodes of ventilator-associated pneumonia received initial broad-spectrum coverage followed by reevaluation according to clinical response and microbiology. Quantitative cultures obtained by bronchoscopic examination or tracheal aspirates were used to modify therapy.
INTERVENTIONS: : None.
MEASUREMENTS AND MAIN RESULTS: One hundred and twenty-one episodes of ventilator-associated pneumonia were diagnosed. Change of therapy was documented in 56.2%, including de-escalation (the most frequent cause) in 31.4% (increasing to 38% if isolates were sensitive). Overall intensive care unit mortality rate was 32.2%. Inappropriate antibiotic therapy was identified in 9% of cases and was associated with 14.4% excess intensive care unit mortality. Quantitative tracheal aspirates and bronchoscopic samples (58 protected specimen brush and three bronchoalveolar lavage) were associated with 32.7% and 29.5% intensive care unit mortality and 29.3% and 34.4% de-escalation rate. De-escalation was lower (p < .05) in the presence of nonfermenting Gram-negative bacillus (2.7% vs. 49.3%) and in the presence of late-onset pneumonia (12.5% vs. 40.7%). When the pathogen remained unknown, half of the patients died and de-escalation was not performed.
CONCLUSION: De-escalation was the most important cause of antibiotic modification, being more feasible in early-onset pneumonia and less frequent in the presence of nonfermenting Gram-negative bacillus. The impact of quantitative tracheal aspirates or bronchoscopic techniques was comparable in terms of mortality.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15640629     DOI: 10.1097/01.ccm.0000145997.10438.28

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  50 in total

Review 1.  Management of antimicrobial use in the intensive care unit.

Authors:  Francisco Álvarez-Lerma; Santiago Grau
Journal:  Drugs       Date:  2012-03-05       Impact factor: 9.546

2.  Outcome in bacteremia associated with nosocomial pneumonia and the impact of pathogen prediction by tracheal surveillance cultures.

Authors:  Pieter Depuydt; Dominique Benoit; Dirk Vogelaers; Geert Claeys; Gerda Verschraegen; Koenraad Vandewoude; Johan Decruyenaere; Stijn Blot
Journal:  Intensive Care Med       Date:  2006-09-16       Impact factor: 17.440

3.  Ventilator-associated pneumonia: diagnosis, treatment, and prevention.

Authors:  Steven M Koenig; Jonathon D Truwit
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

4.  Bronchoalveolar lavage for VAP diagnosis: patients must be sampled before any change of antimicrobial therapy.

Authors:  Jean-François Timsit
Journal:  Intensive Care Med       Date:  2007-08-03       Impact factor: 17.440

5.  What can be expected from antimicrobial de-escalation in the critically ill?

Authors:  Marin H Kollef
Journal:  Intensive Care Med       Date:  2013-11-19       Impact factor: 17.440

6.  De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock.

Authors:  J Garnacho-Montero; A Gutiérrez-Pizarraya; A Escoresca-Ortega; Y Corcia-Palomo; Esperanza Fernández-Delgado; I Herrera-Melero; C Ortiz-Leyba; J A Márquez-Vácaro
Journal:  Intensive Care Med       Date:  2013-09-12       Impact factor: 17.440

Review 7.  [Tarragona strategy--appropriate antibiotic therapy in the ICU].

Authors:  L Engelmann; D V Schmitt
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-03-22       Impact factor: 0.840

8.  Non-adherence to guidelines: an avoidable cause of failure of empirical antimicrobial therapy in the presence of difficult-to-treat bacteria.

Authors:  Frédéric Garcin; Marc Leone; François Antonini; Aude Charvet; Jacques Albanèse; Claude Martin
Journal:  Intensive Care Med       Date:  2009-09-24       Impact factor: 17.440

9.  A trial of discontinuation of empiric vancomycin therapy in patients with suspected methicillin-resistant Staphylococcus aureus health care-associated pneumonia.

Authors:  John M Boyce; Olivia-Fabiola Pop; Odaliz Abreu-Lanfranco; Whitney Y Hung; Ann Fisher; Afshin Karjoo; Benjamin Thompson; Zenon Protopapas
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

10.  De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial.

Authors:  Marc Leone; Carole Bechis; Karine Baumstarck; Jean-Yves Lefrant; Jacques Albanèse; Samir Jaber; Alain Lepape; Jean-Michel Constantin; Laurent Papazian; Nicolas Bruder; Bernard Allaouchiche; Karine Bézulier; François Antonini; Julien Textoris; Claude Martin
Journal:  Intensive Care Med       Date:  2014-08-05       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.